The DRD2 polymorphism — principally the Taq I A1 allele of the dopamine D2 receptor gene — occupies a pivotal position in the depth-psychology corpus as the molecular anchor for reward deficiency syndrome (RDS) and its behavioral sequelae. Kenneth Blum and collaborators constitute the dominant voice, marshalling neurogenetic evidence that an abnormality at the DRD2 locus reduces the density of dopamine receptor sites in mesolimbic reward circuitry, generating a constitutional predisposition toward addictive, compulsive, and impulsive behavior. The corpus tracks the Taq I D2A1 allele across a remarkably broad phenotypic terrain — alcoholism, pathological gambling, smoking, ADHD, Tourette syndrome, and binge eating — establishing a recurrent motif of dopaminergic insufficiency. A secondary thread, drawn from Comings and colleagues and reported by Blum, elaborates the heterosis phenomenon at the DRD2 locus, wherein heterozygotes exhibit more extreme behavioral scores than either homozygote class, complicating simple allelic dosage models. The Lanius volume introduces gene-environment interaction as a corrective frame, situating genetic vulnerability within developmental and epigenetic contexts. Notably, the corpus is sparse on critical appraisals of DRD2 association methodology; it leans heavily toward translational and therapeutic implications, positioning the polymorphism as a diagnostic biomarker amenable to nutraceutical and neuroadaptagen intervention.
In the library
12 passages
RDS results from a dysfunction in the 'brain reward cascade,' a complex interaction among brain neurotransmitters in reward centers of the brain, which directly links abnormal craving behavior with a defect in at least the DRD2 dopamine receptor gene.
This passage establishes the DRD2 gene defect as the molecular foundation of reward deficiency syndrome, linking it causally to dopaminergic insufficiency and abnormal craving.
Blum, Kenneth, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008thesis
Within the past decade, Comings et al have examined the role of the DRD2 gene in a range of behaviors, and have noticed a persistent tendency for quantitative behavioral scores to be highest in 12 heterozygotes, lowest in 11 homozygotes, and intermediate in 22 homozygotes.
This passage articulates the heterosis phenomenon at the DRD2 locus, demonstrating that allelic dosage effects are non-linear and that heterozygosity produces the most extreme behavioral phenotypes.
Blum, Kenneth, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008thesis
the prevalence of the D2A1 allele was approximately two-fold higher than in controls... it was found that 48% carried the Taq I D2A1 allele... The prevalence Taq I D2 A1 allele was even higher in a large group of pathological gamblers.
This passage documents the elevated frequency of the Taq I D2A1 allele across multiple behavioral disorders, supporting the polymorphism's broad relevance to impulsive and addictive phenotypes.
Blum, Kenneth, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008thesis
the DRD2 gene A1 allele is associated with abnormalities in both the P300 latency and amplitude in well-screened alcoholics.
This passage extends the DRD2 A1 allele's clinical significance to electrophysiological biomarkers, linking the polymorphism to P300 abnormalities in alcoholism and suggesting its diagnostic utility.
Blum, Kenneth, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008supporting
the correlation between cerebral spinal fluid homovanilic acid levels and DRD2 genotypes, the correlation between tics and dopamine D2 receptor density in Tourette syndrome.
This passage situates DRD2 genotype within a convergent evidential framework — neuroimaging, CSF metabolites, receptor density — validating its role in dopaminergic regulation across ADHD-spectrum disorders.
Blum, Kenneth, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008supporting
we recommend diagnosis of ADHD using the specific DNA polymorphic analysis coupled with electrophysiological and computerized testing, especially in Jung children.
This passage argues for integrating DRD2 polymorphic analysis into multi-modal ADHD diagnostics, positioning genetic typing as a necessary complement to behavioral and neurophysiological assessment.
Blum, Kenneth, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008supporting
Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk
This bibliographic passage references research interrogating whether DRD2 A1 allele carriers among alcohol-dependent populations carry elevated relapse or dependence risk, contextualizing the polymorphism within treatment-outcome research.
Blum, Kenneth, Early Intervention of Intravenous KB220IV Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study, 2012supporting
Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder.
This citation situates the DRD2 polymorphism within binge eating disorder research, extending the reward deficiency framework from substance addiction to compulsive eating behavior.
Miller, Merlene, Early Intervention of Intravenous KB220IV-Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study, 2012supporting
significant benefits for victims having genetic antecedents for addictive, compulsive, and impulsive behaviors classified under the rubric of reward deficiency syndrome.
This passage affirms the clinical relevance of the DRD2 genetic substrate in the context of neuroadaptagen therapy, framing polymorphism-linked vulnerability as the target of pharmacogenomic intervention.
Blum, Kenneth, Early Intervention of Intravenous KB220IV Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study, 2012supporting
Variations in HPA axis sensitivity to stress may provide a common biological pathway through which other genetic polymorphisms mediate their association with onset of depressive/anxiety disorders in response to stress.
This passage, while not addressing DRD2 directly, establishes the broader gene-environment interaction framework within which DRD2 polymorphism research is implicitly embedded in trauma and stress-diathesis discourse.
Lanius, edited by Ruth A, The impact of early life trauma on health and disease the, 2010aside
decreased levels of dopaminergic efficiency correlate with increased vulnerability to parental stress... the 7-repeat DRD4 polymorphism has been associated with an increased risk for disorganized attachment, but only in the presence of maternal unresolved loss or trauma.
This passage invokes dopamine receptor gene polymorphism logic — here DRD4 — as a comparative case for understanding how genetic variation in dopaminergic systems interacts with early environment, contextualizing DRD2 research within GxE paradigms.
Lanius, edited by Ruth A, The impact of early life trauma on health and disease the, 2010aside
Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients.
This passage references adjacent pharmacogenomic polymorphism research in alcohol dependence, providing a comparative context for DRD2 polymorphism studies without engaging the locus directly.
Brower, Kirk J., Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances, 2010aside